Clinical study of modulated electro-hyperthermia for advanced metastatic breast cancer
Copyright: © Nagata et al..
Modulated electro-hyperthermia (mEHT) is a new treatment modality developed to overcome the problems associated with traditional hyperthermia; mEHT uses a precise impedance-matched system and modulated radiofrequency current flow to malignant tumors. It selects the malignant cells based on their biophysical differences, due to their high metabolic rate, individual (autonomic) behavior and membrane status. The aim of the present study was to report the outcomes of mEHT in the treatment of advanced breast cancer. mEHT was examined in 10 patients with advanced metastatic breast cancer and recurrent disease, who were considered incurable by standard therapy protocols. Of the 10 patients, partial response was achieved in 3, disease stability in 3, and progressive disease in 4; however, their quality of life was improved based on their subjective reports. No adverse effects were observed in any of the 10 patients. The present study demonstrated the feasibility of mEHT as a possible therapy for advanced breast cancer cases when standard therapies fail. Moreover, mEHT had no side effects and may be combined with various treatments for long-term therapy.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
|---|---|
| Enthalten in: |
Molecular and clinical oncology - 14(2021), 5 vom: 07. Mai, Seite 103 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Nagata, Takuya [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Breast cancer |
|---|
| Anmerkungen: |
Date Revised 03.04.2021 published: Print-Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3892/mco.2021.2265 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM323517927 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM323517927 | ||
| 003 | DE-627 | ||
| 005 | 20231225184344.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3892/mco.2021.2265 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1078.xml |
| 035 | |a (DE-627)NLM323517927 | ||
| 035 | |a (NLM)33796292 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Nagata, Takuya |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Clinical study of modulated electro-hyperthermia for advanced metastatic breast cancer |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 03.04.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Copyright: © Nagata et al. | ||
| 520 | |a Modulated electro-hyperthermia (mEHT) is a new treatment modality developed to overcome the problems associated with traditional hyperthermia; mEHT uses a precise impedance-matched system and modulated radiofrequency current flow to malignant tumors. It selects the malignant cells based on their biophysical differences, due to their high metabolic rate, individual (autonomic) behavior and membrane status. The aim of the present study was to report the outcomes of mEHT in the treatment of advanced breast cancer. mEHT was examined in 10 patients with advanced metastatic breast cancer and recurrent disease, who were considered incurable by standard therapy protocols. Of the 10 patients, partial response was achieved in 3, disease stability in 3, and progressive disease in 4; however, their quality of life was improved based on their subjective reports. No adverse effects were observed in any of the 10 patients. The present study demonstrated the feasibility of mEHT as a possible therapy for advanced breast cancer cases when standard therapies fail. Moreover, mEHT had no side effects and may be combined with various treatments for long-term therapy | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a breast cancer | |
| 650 | 4 | |a chemotherapy | |
| 650 | 4 | |a hyperthermia | |
| 650 | 4 | |a irradiation | |
| 700 | 1 | |a Kanamori, Masahiko |e verfasserin |4 aut | |
| 700 | 1 | |a Sekine, Shinichi |e verfasserin |4 aut | |
| 700 | 1 | |a Arai, Mie |e verfasserin |4 aut | |
| 700 | 1 | |a Moriyama, Makoto |e verfasserin |4 aut | |
| 700 | 1 | |a Fujii, Tsutomu |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Molecular and clinical oncology |d 2013 |g 14(2021), 5 vom: 07. Mai, Seite 103 |w (DE-627)NLM236574981 |x 2049-9469 |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2021 |g number:5 |g day:07 |g month:05 |g pages:103 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3892/mco.2021.2265 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2021 |e 5 |b 07 |c 05 |h 103 | ||